- Home
- Publications
- Publication Search
- Publication Details
Title
Current therapy of KRAS-mutant lung cancer
Authors
Keywords
-
Journal
CANCER AND METASTASIS REVIEWS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-16
DOI
10.1007/s10555-020-09903-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- (2020) Alex Friedlaender et al. CANCER TREATMENT REVIEWS
- KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
- (2019) Helen Adderley et al. EBioMedicine
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
- (2019) Lilla Reiniger et al. ACTA ONCOLOGICA
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors
- (2019) Aslamuzzaman Kazi et al. CLINICAL CANCER RESEARCH
- Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
- (2019) Miriam Molina-Arcas et al. Science Translational Medicine
- New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
- (2019) Haitang Yang et al. Frontiers in Oncology
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Cracking KRAS
- (2019) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
- (2019) Ghimessy et al. Cancers
- Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
- (2019) David E. Gerber et al. LUNG CANCER
- Oral bisphosphonate use and lung cancer incidence among postmenopausal women
- (2018) M H Tao et al. ANNALS OF ONCOLOGY
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- KRAS: Reasons for optimism in lung cancer
- (2018) C.R. Lindsay et al. EUROPEAN JOURNAL OF CANCER
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
- (2018) Penelope A. Bradbury et al. LUNG CANCER
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.
- (2018) Jonathan Wade Goldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Farnesyl trasnsferase inhibitors as potential anticancer agents
- (2018) Sounak Bagchi et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis
- (2018) Shi-Ming Zhang et al. Cancer Management and Research
- Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
- (2018) Marcel Wiesweg et al. ONCOGENE
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2017) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
- (2017) Sarah J. Ross et al. Science Translational Medicine
- Direct inhibition of RAS: Quest for the Holy Grail?
- (2017) Russell Spencer-Smith et al. SEMINARS IN CANCER BIOLOGY
- Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
- (2017) Gaowei Fan et al. Oncotarget
- Synthetic Lethal Vulnerabilities in KRAS -Mutant Cancers
- (2017) Andrew J. Aguirre et al. Cold Spring Harbor Perspectives in Medicine
- Use of Ras effector RASSF1A promoter gene methylation and chromosome 9p loss of heterozygosity (LOH) to predict progression-free survival (PFS) in perioperative chemotherapy (CT) phase III trial IFCT-0002 in resectable non-small cell lung cancer
- (2017) G. Zalcman et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
- (2017) Zoltan Lohinai et al. Scientific Reports
- Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
- (2016) C. A. Carter et al. ANNALS OF ONCOLOGY
- Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
- (2016) Stéphane Renaud et al. BRITISH JOURNAL OF CANCER
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy
- (2016) Jonathan W. Goldman et al. Clinical Lung Cancer
- The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- (2016) Vassiliki Papadimitrakopoulou et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2016) Alona Zer et al. Journal of Thoracic Oncology
- Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆
- (2016) Megan L. Hames et al. LUNG CANCER
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models
- (2016) István Kenessey et al. Oncotarget
- Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
- (2016) Boram Lee et al. Oncotarget
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
- (2015) S. Ramalingam et al. ANNALS OF ONCOLOGY
- The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation
- (2015) Fan Xie et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
- (2015) A. D. Cox et al. CLINICAL CANCER RESEARCH
- The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
- (2015) Gemma Bruera et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation
- (2015) Jon J. G. Winter et al. JOURNAL OF MEDICINAL CHEMISTRY
- Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial
- (2015) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Immunogenicity of somatic mutations in human gastrointestinal cancers
- (2015) E. Tran et al. SCIENCE
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab
- (2015) Ondrej Fiala et al. TUMOR BIOLOGY
- Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation
- (2015) Mi-Heon Lee et al. Journal for ImmunoTherapy of Cancer
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
- (2014) S Li et al. BRITISH JOURNAL OF CANCER
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- The clinical relevance of KRAS gene mutation in non-small-cell lung cancer
- (2014) József Tímár CURRENT OPINION IN ONCOLOGY
- Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy
- (2014) Mihaly Cserepes et al. EUROPEAN JOURNAL OF CANCER
- The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma
- (2014) Benjamin Izar et al. Journal of Thoracic Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C
- (2014) J. C. Hunter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
- (2013) Sang Min Lim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- The prognostic and predictive value ofKRASoncogene substitutions in lung adenocarcinoma
- (2013) Liza C. Villaruz et al. CANCER
- Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors
- (2013) Kazunori Honda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
- (2013) G. R. Blumenschein et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers
- (2013) Jamie E. Chaft et al. Journal of Thoracic Oncology
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
- (2013) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis
- (2013) Daquan Meng et al. LUNG CANCER
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
- (2013) Jong-Mu Sun et al. PLoS One
- The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
- (2013) Ondrej Fiala et al. Cancer Genetics
- Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
- (2012) Qi Sun et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy
- (2012) Ji-lin Guan et al. ANNALS OF SURGICAL ONCOLOGY
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer with a KRAS Mutation
- (2012) A.-M. C. Dingemans et al. CLINICAL CANCER RESEARCH
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
- (2012) N. Rekhtman et al. CLINICAL CANCER RESEARCH
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
- (2012) Giulio Metro et al. LUNG CANCER
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
- (2012) T. Maurer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line
- (2011) M. Di Salvatore et al. CELL PROLIFERATION
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
- (2011) Gregory J. Riely et al. Journal of Thoracic Oncology
- Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
- (2011) Vienna Ludovini et al. Journal of Thoracic Oncology
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2010) Shirin Khambata-Ford et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations: A Brief Report
- (2010) Egbert F. Smit et al. Journal of Thoracic Oncology
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now